advertisement

Friday, March 19, 2010
[an error occurred while processing this directive]

Other options

Testosterone levels can be reduced within 24 hours with ketoconazole (Nizoral)—a drug approved by the FDA to treat fungal infections that also inhibits the synthesis of adrenal and testicular androgens. Ketoconazole is used only when lowering androgens rapidly might be beneficial (for example, to alleviate pain). It is used only in the short term, because it raises luteinizing hormone levels, which can cause testosterone levels to rise and disease progression to occur. Ketoconazole can also cause liver problems.

Multimedia

Health Tips from Dr. Healy:
Video: Why cancer patients should stop smoking

Related Links
Bullet Eight steps you can take to reduce your risk of cancer
Bullet Interested in a clinical trial? Here's all you need to know
Bullet See the top online resources for prostate cancer information
Bullet How to lose weight and keep it off
Bullet Prostate Cancer-Related Clinical Trials Information
0
Email this sectionEmail this pagePrint this sectionPrint this section
0
0
0

Flutamide in combination with finasteride has been studied as a treatment option for advanced prostate cancer. Researchers hoped this combination would be effective, since finasteride lowers levels of dihydrotestosterone and could potentially enhance the ability of flutamide to block androgen action. But this approach is less effective than standard hormone therapy using an LH-RH analog or surgical castration.

Content last updated: 8/15/05Previous PagePrevious page Next PageNext Page



Content excerpted from the Johns Hopkins White Paper on Prostate Disorders.




U.S. News's featured content providers were not involved in the selection of advertisers appearing on this website, and the placement of such advertisement in no way implies that these content providers endorse the products and services advertised. Disclaimer and a note about your health.

advertisement

advertisement

advertisement


Copyright © 2007 U.S.News & World Report, L.P. All rights reserved.

Use of this Web site constitutes acceptance of our Terms and Conditions of Use and Privacy Policy.